UNSPSC 51352011: Norgestrel

This classification denotes a therapeutic progestin with the molecular formula C21H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3J8Q1747Z2, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17.alpha.)-(.+/-.)- but generally known as norgestrel, which bears US NIH Compound Identifier 4542. European Medicines Agency schedules Norgestrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09371MIG. The term NORGESTREL is an International Non-Proprietary Name.

UNSPSC 51352011 Norgestrel is a Commodity code covering the supply of this specific oral contraceptive medication through state and local government procurement channels. State and local health departments, Medicaid agencies, public health clinics, and corrections departments procure norgestrel and related generic contraceptive products to support family planning programs, inmate healthcare, and subsidized pharmaceutical access. The drug is typically procured as part of broader generic pharmaceutical supply contracts rather than as a standalone line item, with purchasing driven by formulary inclusion decisions, patient volume forecasting, and negotiated pricing through authorized wholesale distributors. Issuing bodies include state health departments, state Medicaid programs, county public health offices, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions to achieve volume discounts and standardized supply chains.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products, with norgestrel among the covered therapeutic classes. The MMCAP procurement spans participating state and local government facilities across Minnesota and Oregon, requiring vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded agreements effective July 1, 2026. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain relationships with at least two of the three authorized wholesalers with chargeback systems in place, and accept a 3 percent administrative fee. Evaluation weightings emphasize price competitiveness (75 percent) alongside fixed pricing (10 percent), compliance with data format requirements (5 percent), EDI capability (5 percent), and pricing flexibility options including flat price, net price formats, and WAC-minus structures. The contract term is two years for new responders with optional extensions at MMCAP's discretion.